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Abstract
Background—There is limited information on rates of STIs in Jamaica due to syndromic 
management and limited aetiological surveillance. We examined the prevalence of Chlamydia 
trachomatis (CT), Neisseria gonorrhoeae (NG) and Trichomonas vaginalis (TV) and 
characteristics associated with STIs among sexually active women who participated in a 
randomised trial of a progestin implant initiation in Jamaica (the Sino-Implant Study (SIS)).
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Methods—SIS was a randomised trial conducted in Kingston, Jamaica, from 2012 to 2014 to 
evaluate whether initiation of the Sino-Implant (II) led to more unprotected sex among women 
ages 18–44 years. Data collected included self-reported demographic, sexual behaviour 
information; and vaginal swabs collected at baseline, 1-month and 3-month follow-up visits for a 
biomarker of recent semen exposure (prostate-specific antigen (PSA)) and for STIs. We examined 
associations between STIs and PSA, demographics, sexual behaviour and insertion of an implant, 
with a repeated-measures analysis using generalised estimating equations (SAS Institute, V.9.3).
Results—Remnant vaginal swabs from 254 of 414 study participants were tested for STIs. At 
baseline, 29% of participants tested for STIs (n=247) had laboratory-confirmed CT, 5% NG, 23% 
TV and 45% any STI. In a repeated-measures analysis adjusted for study arm (immediate vs 
delayed implant insertion), those with PSA detected did not have an increased prevalence of any 
STI (prevalence ratio (PR)=1.04 (95% CI 0.89 to 1.21)), whereas prevalence decreased for each 1-
year increase in age (PR=0.98 (95% CI 0.97 to 0.99)). Immediate implant insertion was not 
associated with increases in any STI in subsequent visits (PR=1.09 (95% CI 0.94 to 1.27)).
Conclusions—Although the prevalence of laboratory-confirmed STIs was high, the immediate 
initiation of a contraceptive implant was not associated with higher STI prevalence rates over 3 
months.
Trial registration number—NCT01684358.
INTRODUCTION
STIs are a major public health problem worldwide. The WHO estimates that there were 
approximately 125 million new cases of chlamydia, gonorrhoea, syphilis and trichomoniasis 
combined in 2008 in the region of the Americas.1–4 In Jamaica, the STI rates are highest in 
sexually active adolescents, with at least one in four having had an STI.3 These infections 
are often asymptomatic and could lead to serious complications if left untreated.
Correct and consistent use of condoms reduces STI risk.56 Self-reported condom use can be, 
however, affected by measurement error5 and several types of bias including recall bias and 
social desirability bias.6–10 In addition, incorrect use of condoms or a condom breakage 
unbeknownst to the user can lead to inadvertent unprotected sexual exposure and an 
incorrect self-report of condom use.11 Demonstrating an association between biomarkers of 
semen exposure and STI risk would be useful, given limitations of self-report of sensitive 
sexual behaviours.58–17 Semen biomarkers have been recently used in reproductive health 
studies to objectively assess recent vaginal semen exposure,6–16 the efficacy of barrier 
methods of contraception,111819 self-reported condom use14152021 and study protocol 
compliance (when it requires avoidance of unprotected sex).82122 Both Y chromosome–
DNA and prostate-specific antigen (PSA) are biomarkers of semen exposure,67111923 with 
PSA more widely studied and readily available for use in low-resource settings.8–1019–2124 
PSA is detectable in vaginal fluids for up to 48 hours after vaginal exposure to semen.1119 
Further evaluation of biomarkers as objective indicators of semen exposure and STI 
prevalence and incidence is needed.
There is currently only limited information about the correlation of semen biomarkers with 
STI prevalence and incidence7101221 or pregnancy outcomes.13 There is also no information 
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with regard to initiation of long-acting reversible contraceptives (LARCs) and their effects 
on STI for sexually active Jamaican women. For this study, PSA, used as a bio-marker of 
semen exposure, was evaluated for association with laboratory-confirmed STI results 
(Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG) and Trichomonas vaginalis 
(TV)) among women enrolled in Sino-Implant Study (SIS) (a randomised trial)25 of early 
versus delayed contraceptive implant initiation (LARC) in Kingston, Jamaica. We examined 
the prevalence and risk factors associated with STIs in this population.
MATERIALS AND METHODS
The results of SIS have previously been described.25 Briefly, SIS was a randomised 
controlled trial conducted in Jamaica that evaluated whether the initiation of a LARC 
method, the Sino-Implant (II), is associated with reduced condom use. Women were 
randomised to receive the Sino-Implant (II) at the beginning (immediate insertion arm, 
N=208) or at the end (delayed insertion arm, N=206), of a 3-month study period. Vaginal 
swabs for PSA and STI testing were collected at baseline, and at 1-month and 3-month 
follow-up study visits. Study participants were recruited through peer-to-peer referrals or 
from seven maternal and child health and family planning public clinics in Kingston, 
Jamaica, from September 2012 to October 2013 with follow-up until January 2014.
PSA testing was conducted onsite using published procedures for the ABAcard 30 (Abacus 
Diagnostics, West Hills, California, USA), a rapid, semiquantitative test kit. The vaginal 
swab eluate was added to the sample well of the test card, and at 10 min, the results were 
recorded by local study staff, according to the manufacturer’s instructions. Quality assurance 
testing was conducted using a quantitative total PSA assay (Abbott Diagnostics, Abbott 
Park, Illinois, USA) at the US Centers for Disease Control and Prevention.
All participants provided vaginal swab specimens for the study; if swab specimens were not 
used completely for the primary analysis, they were considered remnant and further 
evaluated for additional testing, such as for STI. Remnant specimens were available for STI 
testing from 254 of the 414 (61%) study participants. STI testing was conducted using the 
Aptima Combo 2 assay for CT/NG and the Aptima Trichomonas vaginalis assay with the 
Panther system (Hologic, San Diego, California USA) at the US Centers for Disease Control 
and Prevention. Of the 254 participants, 178 had results available for all three study visits.
Statistical methods
Baseline characteristics for those participants with samples available for STI testing at any 
study visit were described as medians with an IQR for continuous variables and percentages 
for categorical variables. Positive results for lab-confirmed CT, NG and TV were combined 
into a single ‘any STI’ outcome for analysis. Associations between ‘any STI’ at all three 
study visits and demographic and behavioural characteristics were assessed by calculating 
prevalence ratios (PRs) adjusted for study arm using repeated measurements models fit by 
generalised estimating equations. The effect of study arm on STIs was assessed using a 
similar model, using only results from the two follow-up study visits and adjusting for the 
baseline STI outcome. Baseline characteristics were compared between study participants 
with and without specimens available for STI testing using χ2 tests and t-tests, to ensure 
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lack of specimen availability did not introduce bias into the analysis. All analyses were 
conducted using SAS V.9.3 (SAS Institute).
Ethical review
The Consolidated Standards of Reporting Trials guidelines for conducting and reporting 
randomised controlled trials were followed.24
RESULTS
Baseline characteristics of the 254 participants with swabs available for STI testing from at 
least one study visit are shown in table 1. The tested participants did not differ in their 
characteristics between the two study arms. Most participants were single and had 
completed high school. About a quarter in each study arm reported that they used hormonal 
contraception in the past month (table 1). A small proportion of participants reported that 
they drank four or more drinks in a day (4% in each study arm), ever had transactional sex 
(5% in the immediate insertion arm; 6% in the delayed insertion arm) or had more than one 
partner in the past month (7% in the immediate insertion arm; 5% in the delayed insertion 
arm). At enrolment, unprotected sex in the past two days was reported by 17% of 
participants in the immediate insertion arm and 15% of participants in the delayed insertion 
arm, while PSA was detected in 28% of participants in the immediate insertion arm and 23% 
of participants in the delayed insertion arm. There were no differences found in any baseline 
participant characteristics between those who had remnant swabs available for STI testing 
and those who did not.
At baseline, 34% of the participants had laboratory-confirmed CT, 5% NG, 24% TV and 
48% any STI in the immediate insertion arm, and 25% of the participants had laboratory-
confirmed CT, 6% NG, 22% TV and 42% any STI in the delayed insertion arm. At the 3-
month study visit, 43% had CT, 4% NG, 41% TV and 67% any STI in the immediate 
insertion arm, and 35% had CT, 2% NG, 37% TV and 56% any STI in the delayed insertion 
arm (figure 1).
PSA detection was not associated with increased prevalence of an STI (PR=1.04 (95% CI 
0.89 to 1.21)). The prevalence of an STI was higher for those who self-reported unprotected 
sex in the past two days (PR=1.16 (95% CI 0.99 to 1.36)), those who reported being single 
(PR=1.20 (95% CI 0.99 to 1.46)) and those who reported hormonal contraception use in the 
past month (PR=1.18 (95% CI 0.99 to 1.40)). Prevalence of STI decreased for each 1-year 
increase in age (PR=0.98 (95% CI 0.97 to 0.99)) (table 2). Randomisation to immediate 
implant insertion (compared with delayed insertion) was not associated with an increase in 
prevalence of an STI during follow-up visits (PR=1.09 (95% CI 0.94 to 1.27)), adjusted for 
baseline STI result.
DISCUSSION
Although the prevalence of laboratory-confirmed STIs was high in this population of 
sexually active women in Kingston, Jamaica, the immediate initiation of a hormonal 
contraceptive implant (a LARC) did not lead to higher STI rates over 3 months. This finding 
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is similar to that of the primary SIS study findings, which found that unprotected sex, as 
measured by detection of PSA in vaginal secretions, did not increase over the first three 
months of implant use.25 Longer follow-up studies would be needed to confirm this finding, 
but it nevertheless is reassuring. As efforts to promote use of LARC for prevention of 
unintended pregnancy are being scaled up, it will be important to monitor rates of STIs, 
identify markers of higher risk and target STI prevention efforts accordingly.
Our findings seem to be in contrast to a recent cross-sectional study of US high school 
students, which found that condom use was less likely among LARC users compared with 
the students who were taking oral contraceptives.26 Our study is notably different; study 
participants were adults seeking a LARC and Jamaican, we used a longitudinal design and 
we also used bio-markers such as laboratory confirmation of STIs and a marker of vaginal 
semen exposure rather than exclusive reliance on self-report of condom use.
Younger age was associated with increased prevalence of an STI, as has been previously 
reported.1–46 The high prevalence of STIs in this population corroborates the high rate of 
unprotected sex, both self-reported and detected by PSA, in this study. It also confirms 
previous indications of high rates of STIs and unmet contraceptive needs in Jamaica: >85% 
of national survey respondents who were sexually active reported not using any barrier 
method (ie, condoms) to prevent STIs,3 and >3 million adolescents in Latin America and the 
Caribbean have unmet contraception needs.2 Our own study found that only 25% of 
respondents used hormonal contraception in the past month. Although there are not recent 
country-specific rates of STIs for Jamaica, the high rates among study participants indicate a 
pressing need for surveillance, risk reduction strategies and the promotion of dual protection.
Even though significant progress has been made with the use of biomarkers of semen 
exposure in reproductive and sexual health studies, there are still many unanswered 
questions about their utility. In particular, very limited information is available about 
whether their detection correlates with outcomes such as pregnancy or STI acquisition. A 
study which examined the accuracy of self-reported sexual behaviour assessed by detection 
of Y chromosome found that under-reporting semen exposure (positive Y chromosome) 
predicted pregnancy in 6 months but not 12 months longitudinally in a cohort of 
adolescents.13 Two previous studies addressed STIs: a cross-sectional study of 1166 women 
in West Africa showed a strong association between detected PSA in vaginal secretions and 
the presence of NG, CT and Mycoplasma genitalium among female non-sex workers.21 A 
recent study linked PSA positivity to increased recurrence of bacterial vaginosis (BV), while 
notably finding no significant association between self-reported unprotected sex and 
recurrent BV.12
In our study, neither positive biomarker (PSA) nor self-reported unprotected sex in the past 
two days was associated with higher prevalence of STIs. Using the observed rate of any STI, 
this analysis had adequate power (with 80% power to detect a minimum absolute difference 
in STI rate of 11.2% between those testing positive for PSA and those testing negative for 
PSA). One of the limitations of the PSA assay is the short 2-day time frame during which 
PSA is detectable after semen exposure.1219 This short window of time around the clinic 
visits may not be reflective of the behaviours or exposures of the participants throughout the 
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entire study period for SIS. It will be valuable to further investigate semen biomarkers, 
particularly those with longer window of detection after unprotected exposure(s), and 
determine whether the detection correlates with STIs. Additionally, we used a rapid 
qualitative PSA assay, and quality assurance testing indicated that its sensitivity was 84% 
and specificity 81% compared with the ARCHITECT quantitative assay,25 which may also 
account for our findings.
The research regarding LARCs and decreased condom use is limited and has not been 
consistently demonstrated.2526 Our study adds to the existing literature by specifically 
evaluating LARC users and their rates of STIs for SIS study participants. Although the 
prevalence of laboratory-confirmed STIs was high among study participants, the immediate 
initiation of a contraceptive implant was not associated with higher STI rates over 3 months. 
However, we observed exceptionally high rates of STIs in our study population. Efforts to 
meet unmet contraceptive needs must be coupled with enhanced STI risk reduction 
strategies for sexually active Jamaican women.
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Key messages
• Some women who use LARCs may not use condoms or use condoms less 
frequently, which may increase their risk for STIs.
• STI rates were high overall for the Jamaican study participants seeking a 
contraceptive implant.
• The insertion of a contraceptive implant did not lead to higher STI prevalence 
rates in the short term (3 months).
• STI risk reduction strategies should be considered along with the 
contraceptive needs of sexually active Jamaican women.
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Figure 1. 
Prevalence of test results for (A) Chlamydia trachomatis, (B) Neisseria gonorrhoeae, (C) 
Trichomonas vaginalis and (D) any STI by study visit and study arm, Sino-Implant Study, 
Kingston, Jamaica. In total, 254 participants had a swab available for testing for at least one 
of the three study visits.
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Table 1
Baseline characteristics of Sino-Implant Study participants tested for STIs at one or more study visits (N=254) 
by study arm, Kingston, Jamaica
Immediate insertion arm (N=123)
n (%)
Delayed insertion arm (N=131)
n (%)
Single, never married 79 (64.2) 98 (74.8)
Did not complete high school 41 (33.3) 33 (25.2)
Hormonal contraception in the past month 29 (23.6) 36 (27.5)
More than one partner in the past month 8 (6.5) 7 (5.3)
Four or more alcoholic drinks in 1 day in the past week 4 (3.6) 5 (4.2)
Ever received money or gifts in exchange for sex 6 (4.9) 8 (6.1)
Positive prostate-specific antigen test 34 (27.6) 30 (22.9)
Self-reported unprotected sex in the past two days 21 (17.1) 19 (14.5)
Median (IQR) Median (IQR)
Age (years) 25 (21–29) 25 (21–30)
Parity 2 (1–3) 2 (1–3)
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Table 2
Associations between participant characteristics and any STI, the Sino-Implant Study, Kingston, Jamaica
Prevalence ratio* 95% CI
Positive prostate-specific antigen test 1.04 0.89 to 1.21
Self-reported unprotected sex in the past two days 1.16 0.99 to 1.36
Age (per increase of 1 year) 0.98 0.97 to 0.99
Parity (per increase of 1) 0.97 0.91 to 1.05
Single, never married 1.20 0.99 to 1.46
Did not complete high school 1.10 0.93 to 1.30
Four or more alcoholic drinks in 1 day in the past week 1.14 0.77 to 1.69
Ever received money or gifts in exchange for sex 0.96 0.68 to 1.36
Hormonal contraception in the past month 1.18 0.99 to 1.40
More than one partner in the past month 1.05 0.80 to 1.37
*Adjusted for study arm.
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